Key Points
- Insider purchase: Director Nick Roberts bought 90 shares on April 30 at an average price of GBX 167 per share (total £150.30) and had previously purchased 100 shares on March 2 at GBX 150.
- Analyst sentiment: Shore Capital raised its price target to GBX 215 and gave a "buy" rating; Diaceutics has a consensus "Buy" from three analysts with an average price target of GBX 193.33.
- Stock snapshot: The stock opened at GBX 167 (up ~1.2%), has a market capitalization of £141.33 million, a 12‑month range of GBX 112.25–177, and 50/200‑day moving averages around GBX 155.
Diaceutics PLC (LON:DXRX - Get Free Report) insider Nick Roberts purchased 90 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was bought at an average cost of GBX 167 per share, for a total transaction of £150.30.
Nick Roberts also recently made the following trade(s):
- On Monday, March 2nd, Nick Roberts purchased 100 shares of Diaceutics stock. The stock was bought at an average cost of GBX 150 per share, for a total transaction of £150.
Diaceutics Trading Up 1.2%
LON:DXRX opened at GBX 167 on Wednesday. The company has a current ratio of 3.96, a quick ratio of 9.92 and a debt-to-equity ratio of 3.05. The stock has a market capitalization of £141.33 million, a PE ratio of -92.78 and a beta of 0.94. The firm's 50 day moving average is GBX 154.78 and its 200 day moving average is GBX 153.66. Diaceutics PLC has a 12 month low of GBX 112.25 and a 12 month high of GBX 177.
Analyst Upgrades and Downgrades
Separately, Shore Capital Group lifted their price target on shares of Diaceutics from GBX 180 to GBX 215 and gave the stock a "buy" rating in a report on Thursday, January 15th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Diaceutics has a consensus rating of "Buy" and an average price target of GBX 193.33.
View Our Latest Research Report on Diaceutics
Diaceutics Company Profile
(
Get Free Report)
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
